Stock comparison
Novartis AG is 18.1x more valuable than GENMAB A/S by market capitalization ($295.04 B vs $16.27 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
NVS is larger
Novartis AG is 18.1x more valuable than GENMAB A/S by market capitalization ($295.04 B vs $16.27 B).
Market value leader
NVS
Novartis AG is 18.1x more valuable than GENMAB A/S by market capitalization ($295.04 B vs $16.27 B).
| Metric | GMAB | NVS |
|---|---|---|
| Market cap | $16.27 B | $295.04 B |
| US-listed rank | #694 | #46 |
| Net margin | - | - |
| P/E (trailing FY) | - | - |
| SEC filings | 540 | 981 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Novartis AG is 18.1x more valuable than GENMAB A/S by market capitalization ($295.04 B vs $16.27 B).
Full pages: GENMAB A/S and Novartis AG, or browse the full rankings.